US FDA Priority Review Voucher Fee Continues Drop In FY 2020

 
• By Derrick Gingery
FDABldg1ExteriorWithCircle_1200x675
The US FDA expects some revenue from priority review voucher redemptions in FY 2020, suggesting a few vouchers may be used. • Source: File photo

More from Review Pathways

More from Pathways & Standards